Biomedicine & Pharmacotherapy (Jan 2024)

Rhogef17: A novel target for endothelial barrier function

  • Zhuolin Wu,
  • Quanlei Liu,
  • Yan Zhao,
  • Chaonan Fang,
  • Wen Zheng,
  • Zilin Zhao,
  • Nai Zhang,
  • Xinyu Yang

Journal volume & issue
Vol. 170
p. 115983

Abstract

Read online

ARHGEF17 encodes the protein RhoGEF17, which is highly expressed in vascular endothelial cells. It is a guanine nucleotide exchange factor (GEF) that accelerates the exchange of GDP with GTP on many small GTPases through its Dbl homology (DH) domain, enabling the activation of Rho-GTPases such as RhoA, RhoB, and RhoC. Rho GTPase-regulated changes in the actin cytoskeleton and cell adhesion kinetics are the main mechanisms mediating many endothelial cell (EC) alterations, including cell morphology, migration, and division changes, which profoundly affect EC barrier function. This review focuses on ARHGEF17 expression, activation and biological functions in ECs, linking its regulation of cellular morphology, migration, mitosis and other cellular behaviors to disease onset and progression. Understanding ARHGEF17 mechanisms of action will contribute to the design of therapeutic approaches targeting RhoGEF17, a potential drug target for the treatment of various endothelium-related diseases, Such as vascular inflammation, carcinogenesis and transendothelial metastasis of tumors.

Keywords